☰

Utpal B. Pajvani, Ph.D. - Publications

Affiliations: 
2005 Yeshiva University, New York, NY, United States 
Area:
Cell Biology, Animal Physiology Biology, Molecular Biology
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J, Accili D. Author Correction: Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nature Medicine. PMID 38041001 DOI: 10.1038/s41591-023-02695-9  0.352
2023 Cook JR, Hawkins MA, Pajvani UB. Liver insulinization as a driver of triglyceride dysmetabolism. Nature Metabolism. 5: 1101-1110. PMID 37460842 DOI: 10.1038/s42255-023-00843-6  0.52
2022 Aaron N, Zahr T, He Y, Yu L, Mayfield B, Pajvani UB, Qiang L. Acetylation of PPARγ in macrophages promotes visceral fat degeneration in obesity. Life Metabolism. 1: 258-269. PMID 37213714 DOI: 10.1093/lifemeta/loac032  0.336
2022 Oh AR, Jeong Y, Yu J, Minh Tam DT, Kang JK, Jung YH, Im SS, Lee SB, Ryu D, Pajvani UB, Kim K. Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization. Gastroenterology. PMID 36402191 DOI: 10.1053/j.gastro.2022.11.019  0.3
2022 He Y, B'nai Taub A, Yu L, Yao Y, Zhang R, Zahr T, Aaron N, LeSauter J, Fan L, Liu L, Tazebay R, Que J, Pajvani U, Wang L, Silver R, et al. PPARγ Acetylation Orchestrates Adipose Plasticity and Metabolic Rhythms. Advanced Science (Weinheim, Baden-Wurttemberg, Germany). e2204190. PMID 36394167 DOI: 10.1002/advs.202204190  0.4
2021 Wang L, Yu J, Zhou Q, Wang X, Mukhanova M, Du W, Sun L, Pajvani UB, Accili D. TOX4, an insulin receptor-independent regulator of hepatic glucose production, is activated in diabetic liver. Cell Metabolism. PMID 34914893 DOI: 10.1016/j.cmet.2021.11.013  0.503
2021 Kim K, Kang JK, Jung YH, Lee SB, Rametta R, Dongiovanni P, Valenti L, Pajvani UB. Adipocyte PHLPP2 inhibition prevents obesity-induced fatty liver. Nature Communications. 12: 1822. PMID 33758172 DOI: 10.1038/s41467-021-22106-2  0.47
2020 Richter LR, Wan Q, Wen D, Zhang Y, Yu J, Kang JK, McKinnon EL, Gu Z, Qiang L, Pajvani UB. Targeted Delivery of Notch Inhibitor Attenuates Obesity-Induced Glucose Intolerance and Liver Fibrosis. Acs Nano. PMID 32441510 DOI: 10.1021/Acsnano.0C01007  0.319
2019 BARTOLOME A, PAJVANI U. 109-OR: Notch Signaling Controls Islet Architecture and ß-Cell Function in the Developed Pancreas Diabetes. 68: 109-OR. DOI: 10.2337/Db19-109-Or  0.316
2018 Kim K, Goldberg IJ, Graham MJ, Sundaram M, Bertaggia E, Lee SX, Qiang L, Haeusler RA, Metzger D, Chambon P, Yao Z, Ginsberg HN, Pajvani UB. γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. Cell Metabolism. PMID 29576536 DOI: 10.1016/J.Cmet.2018.02.010  0.34
2018 Ballon JS, Pajvani UB, Mayer LE, Freyberg Z, Freyberg R, Contreras I, Rosenbaum M, Leibel RL, Lieberman JA. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. Journal of Psychopharmacology (Oxford, England). 269881118754708. PMID 29444618 DOI: 10.1177/0269881118754708  0.409
2017 Kim K, Ryu D, Dongiovanni P, Ozcan L, Nayak S, Ueberheide B, Valenti L, Auwerx J, Pajvani UB. Degradation of PHLPP2 by KCTD17, via a Glucagon-dependent Pathway, Promotes Hepatic Steatosis. Gastroenterology. PMID 28859855 DOI: 10.1053/J.Gastro.2017.08.039  0.384
2016 Valenti L, Bugianesi E, Pajvani U, Targher G. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes? Liver International : Official Journal of the International Association For the Study of the Liver. 36: 1563-1579. PMID 27276701 DOI: 10.1111/liv.13185  0.338
2016 Sparling DP, Yu J, Kim K, Zhu C, Brachs S, Birkenfeld AL, Pajvani UB. Adipocyte-specific blockade of gamma-secretase, but not inhibition of Notch activity, reduces adipose insulin sensitivity. Molecular Metabolism. 5: 113-21. PMID 26909319 DOI: 10.1016/j.molmet.2015.11.006  0.462
2015 Abraham A, Rubin M, Accili D, Bilezikian JP, Pajvani UB. Hypoglycemia Secondary to Sulfonylurea Ingestion in a Patient with End Stage Renal Disease: Results from a 72-Hour Fast. Case Reports in Endocrinology. 2015: 742781. PMID 26664768 DOI: 10.1155/2015/742781  0.36
2015 Pajvani UB, Accili D. The new biology of diabetes. Diabetologia. 58: 2459-68. PMID 26248647 DOI: 10.1007/s00125-015-3722-5  0.325
2013 Valenti L, Mendoza RM, Rametta R, Maggioni M, Kitajewski C, Shawber CJ, Pajvani UB. Hepatic notch signaling correlates with insulin resistance and nonalcoholic fatty liver disease. Diabetes. 62: 4052-62. PMID 23990360 DOI: 10.2337/db13-0769  0.382
2012 Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SK, Wronska A, Chen BX, Marks AR, Fukamizu A, Backs J, Singer HA, Yates JR, Accili D, Tabas I. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metabolism. 15: 739-51. PMID 22503562 DOI: 10.1016/J.Cmet.2012.03.002  0.367
2011 Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J, Accili D. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nature Medicine. 17: 961-7. PMID 21804540 DOI: 10.1038/Nm.2378  0.522
2007 Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 56: 2174-7. PMID 17513700 DOI: 10.2337/Db07-0185  0.593
2006 Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, Trumbauer ME, Pang Z, Chen AS, Ruderman NB, Chen H, Rossetti L, Scherer PE. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. The Journal of Biological Chemistry. 281: 2654-60. PMID 16326714 DOI: 10.1074/Jbc.M505311200  0.779
2005 Trujillo ME, Pajvani UB, Scherer PE. Apoptosis through targeted activation of caspase 8 ("ATTAC-mice"): novel mouse models of inducible and reversible tissue ablation. Cell Cycle (Georgetown, Tex.). 4: 1141-5. PMID 16096375 DOI: 10.4161/Cc.4.9.2030  0.501
2005 Pajvani UB, Trujillo ME, Combs TP, Iyengar P, Jelicks L, Roth KA, Kitsis RN, Scherer PE. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nature Medicine. 11: 797-803. PMID 15965483 DOI: 10.1038/Nm1262  0.728
2005 Bouskila M, Pajvani UB, Scherer PE. Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity? International Journal of Obesity (2005). 29: S17-23. PMID 15711577 DOI: 10.1038/Sj.Ijo.0802908  0.688
2004 Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, Pajvani UB, Scherer PE, LeRoith D. Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia. 47: 2215-25. PMID 15662559 DOI: 10.1007/S00125-004-1581-6  0.573
2004 Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes. 53: 1671-9. PMID 15220189 DOI: 10.2337/Diabetes.53.7.1671  0.777
2004 Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 53: 1621-9. PMID 15161771 DOI: 10.2337/Diabetes.53.6.1621  0.683
2004 Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in the brain to decrease body weight. Nature Medicine. 10: 524-9. PMID 15077108 DOI: 10.1038/Nm1029  0.716
2004 Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, Wagner JA, Wu M, Knopps A, Xiang AH, Utzschneider KM, Kahn SE, Olefsky JM, Buchanan TA, Scherer PE. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. The Journal of Biological Chemistry. 279: 12152-62. PMID 14699128 DOI: 10.1074/Jbc.M311113200  0.778
2004 Combs TP, Pajvani UB, Berg AH, Lin Y, Jelicks LA, Laplante M, Nawrocki AR, Rajala MW, Parlow AF, Cheeseboro L, Ding YY, Russell RG, Lindemann D, Hartley A, Baker GR, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 145: 367-83. PMID 14576179 DOI: 10.1210/En.2003-1068  0.759
2004 Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Erratum: Adiponectin acts in the brain to decrease body weight Nature Medicine. 10: 649-649. DOI: 10.1038/Nm0604-649A  0.628
2003 Pajvani UB, Scherer PE. Adiponectin: systemic contributor to insulin sensitivity. Current Diabetes Reports. 3: 207-13. PMID 12762967 DOI: 10.1007/S11892-003-0065-2  0.705
2003 Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. The Journal of Biological Chemistry. 278: 9073-85. PMID 12496257 DOI: 10.1074/Jbc.M207198200  0.74
Show low-probability matches.